Crystal Adam 4

What Happened
Crystal Adam, President, R&D of Tango Therapeutics (TNGX), received equity awards and had an automatic sell-to-cover transaction. On Feb 2, 2026 she was granted RSU-based awards totaling 332,220 units (47,460 + 284,760 RSUs). On Feb 3, 2026 she sold 18,251 shares at a weighted average price of $12.26 (proceeds $223,708) and 201 shares at a weighted average price of $12.90 (proceeds $2,592), for total proceeds of about $226,300. The awards are reported at $0 acquisition price because they are RSUs/derivative awards.

Key Details

• Transaction dates: Grants dated Feb 2, 2026; sales on Feb 3, 2026. Form filed Feb 4, 2026 (timely).
• Grants: 47,460 RSUs + 284,760 derivative RSUs = 332,220 RSU-related units granted (no cash paid).
• Sales: 18,251 shares @ weighted avg $12.26 (range $11.88–$12.875) and 201 shares @ weighted avg $12.90 (range $12.88–$12.91); total proceeds ≈ $226,300.
• Shares owned after the transactions: not specified in the provided filing.
• Footnotes: F1 describes that the RSUs vest over three years (33% on Feb 1, 2027; 33% on Feb 14, 2028; 34% on Feb 12, 2029, subject to continued service). F2 states the sales were automatic "sell-to-cover" to satisfy tax withholding (not discretionary). F3/F4 give price ranges and note more detailed breakdowns are available on request. F5 describes an option vesting schedule but no option exercise or option sale is reported in this filing.

Context
The sales here were reported as automatic sell-to-cover transactions to satisfy tax withholding obligations associated with RSU vesting (per the filing), which is a routine administrative action rather than an express directional bet on the stock. The RSU grants are derivative awards that will convert to shares only as they vest per the schedule above.